GAITHERSBURG, Md., March 3, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the fourth quarter and year ended December 31, 2010 on Thursday, March 10, 2011 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, March 11, 2011 to discuss the company's 2010 financial results and 2011 business outlook.
To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 47418441. An audio replay of the conference call will be available starting at 1:00 p.m. EST on March 11, 2011 through March 18, 2011. To listen to the audio replay, dial 800-642-1687 or 706-645-9291 and use Conference Replay ID: 47418441.
A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."
About GenVecGenVec, Inc. is a biopharmaceutical company using superior, proprietary technology to create differentiated vaccines and therapeutics that are developed and commercialized through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the US Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), HSV-2, dengue fever, influenza, HIV, malaria, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.Investor and Media Contact:GenVec, Inc. Douglas J. Swirsky (240) 632-5510 firstname.lastname@example.org
|SOURCE GenVec, Inc.|
Copyright©2010 PR Newswire.
All rights reserved